LSE:AZNPharmaceuticals
AstraZeneca Advances Obesity And Oncology Programs With New Data Catalysts
AstraZeneca has advanced its oral weight loss drug elecoglipron into Phase III trials after meeting key Phase II targets.
The FDA has granted Priority Review to cancer drug DATROWAY for triple negative breast cancer.
Imfinzi has received a positive recommendation in Europe for approval in early stage gastric cancer.
AstraZeneca, LSE:AZN, is pushing ahead on several fronts at once, with fresh momentum in obesity and oncology. The shares most recently closed at £148.18, and the stock is up...